Glaxo strikes $1.9 billion deal for Sierra Oncology

0
86
By Ian Walker

Pharmaceutical giant GlaxoSmithKline PLC said Wednesday that it is buying biopharmaceutical company Sierra Oncology Inc. for $1.9 billion, and backed its guidance.

GlaxoSmithKline will pay $55 per share in cash, a 39% premium to its closing price of $39.52 on Tuesday. The deal has the support of Sierra’s board as well as shareholders owning 28% of its stock.

Glaxo reaffirmed its guidance. It expects 2021-2026 sales growth of more than 5% and for 10% adjusted operating profit.

The deal is expected to close in the third quarter of this year.

Write to Ian Walker at ian.walker@wsj.com


This article was originally published by Marketwatch.com. Read the original article here.

Previous articleMarket Extra: Peak inflation? What’s next for U.S. as markets debate hottest CPI in more than 40 years.
Next articleDow Jones Newswires: Tesco profit jumps as revenue rises faster than forecast

LEAVE A REPLY

Please enter your comment!
Please enter your name here